Advanced Medical Solutions Share Discussion Threads

[bjfanc] 04/6/2013 23:20

Then to to the right under downloads. AGM 2013.

[pedr01] 04/6/2013 13:23

2361: Can you post a link to the slides BJ ? I can't find it for the love of trying ...

[dealit] 04/6/2013 06:06

Yes Norbus I agree, when reading the RNS it was like greeting an old friend I had not seen for a long time.

[norbus] 03/6/2013 18:32

I hope this will mark the turn into better fortunes; This is what AMS used to do well, and should have stuck to it instead of lining Private equity pockets buying
Ribosa.

Way to go, but that is the right track

[jmf69] 03/6/2013 12:38

Fda approval

[bjfanc] 23/5/2013 18:34

Didn't make it. But the AGM slides read well on their website. Looking forward to the full update next month.

[jmf69] 22/5/2013 19:39

Anyone go to the agm ?? Any updates very welcome

[dealit] 22/5/2013 07:14

Trading in line with market expectation for 2013, steady as will go I suppose.

[bjfanc] 21/5/2013 19:06

Google shows they are a US based specialist in small and mid cap stocks ex US.

[dennis russell] 21/5/2013 18:27

Anyone know about KABOUTER, which has emerged over the 3% threshold?

[apad] 23/4/2013 08:26

bj
It wasn't a full article in the IC. Part of a top 100 AIM stocks feature.
I'd be interested in a report of the AGM. Marketing in the US is a perilous business!
apad

[bjfanc] 23/4/2013 07:54

Might go to the AGM next month. Would be good if there was remote access, so you could login in from home to watch. IC article, only gives a small part of the story.

[dealit] 23/4/2013 06:26

Nice to see 80p again with no news.

[apad] 20/4/2013 13:37

From IC

Closing wounds without needing to stitch them is considerably easier for doctors, as well as more comfortable for patients who tend to see their wounds heal faster. Advanced Medical Solutions (AMS) is another Aim company that has built up an interesting medical niche with its Liquiband wound sealant product.
   Expansion over the past few years has come mainly in Europe where AMS bought German surgical sutures company RESORBA for £55m back in 2011, which helped to boost AMS's subsequent reported revenues by 50 per cent. However, the company has struggled to make any real in-roads in the key US hospital market by finding itself stuck in a non-performing contract with a US-based distributor. AMS can extract itself from the agreement without too much hassle but it illustrates the main risk with medical devices companies that attempt to break into new markets – namely, the tendency for larger companies and distributors to sit on products, rather than try to market them aggressively.
   So AMS has to find a strategy that can promote Liquiband – which rates highly in comparison with similar products – successfully. Potential investors should probably expect the company to set up its own business in the US in order to compete effectively. Hold. JH

[jmf69] 17/4/2013 17:33

Moving back up

[texaspete2] 06/3/2013 14:46

Dealit, yeah i noted that, shows a good approach, adapting the product to customer needs. I'm very happy to be in this share

[dealit] 06/3/2013 14:08

I am suprised no one else has picked up on the statement addressing the Liquiband USA situation, sounds their will be anannoucement in the H2 2013 period.

[apad] 06/3/2013 09:49

Nice little VALU share with potential now.
Concerns laid to rest.
Good cash flow as best I can see.
PER/Price to cash flow/price to free cash flow similar :-)
It's the same sort of transformational story to BQE (which I am increasing), but at an earlier stage.
Happy to hold AMS while it bubbles away.
apad

[colsmith] 06/3/2013 09:18

Cash generation looks good with big reduction in debt - getting near to no debt!

[norbus] 06/3/2013 08:59

Cash has ever been king. The areas I mentioned were very healthy pre eyes going off the ball onto takeovers. Natural for house to push share price to the 72 they placed the acquisition funding shares at.

If they find much more room to sell the commodity type products into Europe, then they will have the cash to manoeuvre.

[bjfanc] 06/3/2013 08:38

Cash is king. Resorba is the cash cow, to finance the areas you mention. Yes the acq. meant considerable management focus in 2012. But thats done. The niche products are still their growing and the reliance on 3rd parties, which cause lumpy sales revenue is reduced.

[zipstuck] 06/3/2013 08:13

I agree - limp fotward llooking ststement from outgoing chairman

[norbus] 06/3/2013 07:35

bj

I am really sad the way this once beautiful business was transformed. You be after a dividend, you buy a solid blue chip. AMS was about an organic growth story with a knack to find great niche products for pretty solid markets, and a great route into these markets.

Board changes long overdue, I think Chris and Mary will need some flair alongside and to dump all others as soon as practicable. They will have to trim the sails and try and refocus to where they operated well. The growth engines seem to have gone cold, and I see no evidence of R&D output or the divisional managers they hired pre takeover.

I hope they get sorted before too long,

cgequityinvest has not given us any benefit of his advice for some time, and WT seems to have followed the same path I had taken. Good Luck.

[bjfanc] 06/3/2013 07:32

Foam growth is expected as well in 2013. This had a big effect on 2012 sales revenue. Big improvement in margins.